# Ardelyx to Report First Quarter 2026 Financial Results on April 30, 2026
Canonical URL: https://biopharmsignal.com/news/ARDX/ardelyx-to-report-first-quarter-2026-financial-results-on-april-30-2026-9921f828
Ticker: ARDX
Company: Ardelyx
Source: Ardelyx
Published: 2026-04-16 12:01 EST
## Summary

Conference call scheduled for 4:30 p.m. Eastern Time April 16, 2026 08:01 ET | Source: Ardelyx, Inc. ...

## Article Body
Conference call scheduled for 4:30 p.m. Eastern Time

April 16, 2026 08:01 ET | Source: Ardelyx, Inc.

WALTHAM, Mass., April 16, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX) (“Ardelyx” or the “Company”), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs, today announced that management will host a webcast and conference call on Thursday, April 30, 2026, at 4:30 p.m. Eastern Time to discuss financial results and provide a business update from the first quarter of 2026.

Webcast Information A live webcast of the conference call and accompanying slides will be available in the “Events and Presentations” section under “News and Events” within the Investors section of the Company’s website at www.ardelyx.com .

An archived replay of the webcast and related presentation materials will be available on the Company’s website following the event.

Conference Call Details Domestic (toll-free): 877-346-6112 International (toll): +1 848-280-6350

About Ardelyx

Ardelyx is a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs. Ardelyx has two commercial products approved in the United States, IBSRELA ® (tenapanor) and XPHOZAH ® (tenapanor). The company’s pipeline includes the Phase 3 development of IBSRELA for chronic idiopathic constipation (CIC) and RDX10531, a next-generation NHE3 inhibitor with potential application across multiple therapeutic areas. Ardelyx works with its partners to develop and commercialize its products outside of the United States. For more information, please visit https://ardelyx.com/ and connect with us on X (formerly known as Twitter) , LinkedIn and Facebook .

Investor Contact: Lisa Caperelli lcaperelli@ardelyx.com
## Recent Company News
- 2026-07-23 12:01 EST — [Ardelyx to Report Second Quarter 2026 Financial Results on August 6, 2026](https://biopharmsignal.com/news/ARDX/ardelyx-to-report-second-quarter-2026-financial-results-on-august-6-2026-cf11d40a) — Source: Ardelyx
- 2026-05-19 12:01 EST — [Ardelyx to Participate at the Jefferies Global Healthcare Conference 2026](https://biopharmsignal.com/news/ARDX/ardelyx-to-participate-at-the-jefferies-global-healthcare-conference-2026-a45950e8) — Source: Ardelyx
- 2026-05-07 12:01 EST — [Ardelyx Presents Analysis Supporting Long-Term Safety of XPHOZAH at NKF’s Spring Clinical Meetings](https://biopharmsignal.com/news/ARDX/ardelyx-presents-analysis-supporting-long-term-safety-of-xphozah-at-nkf-s-spring-06ad1b71) — Source: Ardelyx
- 2026-04-30 20:01 EST — [Ardelyx Reports First Quarter 2026 Financial Results and Provides Business Update](https://biopharmsignal.com/news/ARDX/ardelyx-reports-first-quarter-2026-financial-results-and-provides-business-updat-8ab879af) — Source: Ardelyx
- 2026-04-27 12:01 EST — [Ardelyx Announces Abstract Accepted for Poster Presentation at the NKF’s Spring Clinical Meetings](https://biopharmsignal.com/news/ARDX/ardelyx-announces-abstract-accepted-for-poster-presentation-at-the-nkf-s-spring--6ee5c2f6) — Source: Ardelyx
## Related News
- 2026-07-29 14:05 EST — CAPR — [The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy](https://biopharmsignal.com/news/CAPR/the-lancet-publishes-hope-3-data-for-capricor-therapeutics-deramiocel-in-duchenn-9e6e6bd9)
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)